Markets · 1 sources covering this

Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full

India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

MintLean R·2h ago
Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
Read at Mint →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/a0d813c407cc59a6e2bfd2005e89bf27c1ff2a57"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full"></iframe>

Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full

How 1 sources are covering this

Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full

More from Markets

India's hospitality companies' revenue to grow 7-9% in FY27, West Asia conflict poses downside risks: ICRA

Bharti Airtel Q1 Results: Profit climbs on higher subscriber upgrades, robust data usage

Competing cues, caution ahead of RBI policy decision keep rupee nearly flat

Bharti Airtel Q1 results: Net profit jumps 37% to ₹8,167 crore; revenue up 18% - Key highlights

Reader

Trust & legal

Across the network